Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Ezetimibe.

Matthey Harris1, Warren Davis, W Virgil Brown

  • 1Department of Medicine, Emory University, Atlanta, GA, USA.

Drugs of Today (Barcelona, Spain : 1998)
|May 14, 2003
PubMed
Summary
This summary is machine-generated.

Ezetimibe, a novel cholesterol absorption inhibitor, effectively lowers LDL cholesterol by targeting intestinal sterol transport. It offers a new treatment for phytosterolemia and complements statin therapy for hypercholesterolemia.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Mutational landscape of triple-negative breast cancer in African American women.

Nature genetics·2025
Same author

Associations of DNA methylation in breast tumour subtypes with parity and breastfeeding in a cohort of 1459 Black women: implications for public health.

BMJ oncology·2025
Same author

Early screening and diagnosis of gestational diabetes mellitus (GDM) and its impact on perinatal outcomes.

Diabetes research and clinical practice·2024
Same author

COVID-19 lockdowns affected birthing outcomes in a regional New South Wales Health District.

The Australian & New Zealand journal of obstetrics & gynaecology·2024
Same author

Clinical, Epidemiologic, and Pathologic Significance of ERBB2-Low Expression in Breast Cancer.

JAMA network open·2024
Same author

Feeding signals inhibit fluid-satiation signals in the mouse lateral parabrachial nucleus to increase intake of highly palatable, caloric solutions.

Journal of neurochemistry·2023

Area of Science:

  • Pharmacology
  • Gastroenterology
  • Metabolic Diseases

Background:

  • Ezetimibe represents a new drug class targeting intestinal cholesterol absorption.
  • It acts on the apical membrane of intestinal epithelial cells, interfering with sterol transport.
  • Its mechanism differs from phytosterol esters and phytostanol esters.

Purpose of the Study:

  • To elucidate the mechanism of action of ezetimibe.
  • To evaluate its efficacy in lowering cholesterol and other lipids.
  • To assess its potential in treating hypercholesterolemia and phytosterolemia.

Main Methods:

  • Ezetimibe is absorbed and glucuronidated in intestinal cells.
  • It undergoes hepatic uptake and biliary excretion, leading to enterohepatic recycling.

Related Experiment Videos

  • Pharmacokinetic studies assessed its absorption, distribution, metabolism, and excretion.

    • Main Results:

    • Ezetimibe significantly reduces low-density lipoprotein cholesterol (LDLc) by 16-25%.
    • It also reduces chylomicron cholesterol, triglycerides, and modestly increases high-density lipoprotein cholesterol (HDLc).
    • Combination therapy with statins shows additive LDLc reduction and improved lipid profiles. It is effective in homozygous familial hypercholesterolemia and phytosterolemia.

    Conclusions:

    • Ezetimibe is an effective agent for lowering LDL cholesterol.
    • Its unique mechanism provides a new therapeutic option for lipid management, including rare genetic disorders.
    • The drug's pharmacokinetic profile supports once-daily dosing and combination therapy.